ArticleJACC. Advances2026
Impacts of Remnant Cholesterol and Residual Inflammation on Clinical Outcomes After Ischemic Stroke.
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough remnant cholesterol (RC) and residual inflammation are established risk factors for stroke, their joint prognostic value for ischemic stroke remains unclear.
objectivesThe authors aimed to evaluate the combined effects of RC and high-sensitivity C-reactive protein (hs-CRP), as well as a novel index-the remnant cholesterol-inflammation index (RCII)-for long-term clinical outcomes after ischemic stroke.
methodsWe measured RC and hs-CRP levels in 3,008 participants from the China Antihypertensive Trial in Acute Ischemic Stroke. Participants were categorized into 4 groups according to dichotomized RC (≥median, 28.62 mg/dL) and hs-CRP (≥threshold, 2.00 mg/L). RCII was calculated as (RC [mg/dL]×hs-CRP [mg/L])/10 to quantify their joint effects. The study outcomes included all-cause mortality, cardiovascular events, and unfavorable functional outcome at 24 months.
resultsCompared with patients with no residual risk, HRs or ORs for those with residual cholesterol and inflammation risk were 2.33 (95% CI: 1.57-3.44) for all-cause mortality, 2.28 (95% CI: 1.49-3.49) for stroke-specific mortality, and 1.91 (95% CI: 1.44-2.53) for unfavorable functional outcome. In addition, the highest quartile of RCII exhibited increased risks of all-cause mortality, cardiovascular events, and unfavorable functional outcome. Both combined RC/hs-CRP and RCII offered substantial risk discrimination and reclassification improvement for study outcomes beyond traditional risk factors, as evidenced by an increase in C-statistics, net reclassification index, and integrated discrimination improvement.
conclusionsElevated RC and hs-CRP were synergistically associated with increased risks of long-term all-cause mortality and unfavorable functional outcome, and RCII manifested dose-dependent associations with adverse clinical outcomes and superior predictive capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.